What is the FLASH study?
The FLASH study is a clinical research study for people with moderate-to-severe asthma that cannot control their asthma with their current treatment alone. The investigational drug, AZD5718, is a tablet that can be taken once a day at home and is being developed as a potential treatment for heart disease, kidney disease, as well as asthma. Investigational drugs are not approved to be prescribed for treatment at this time as they are still being evaluated in clinical studies such as the FLASH study. The FLASH Study is approximately 19 weeks long.
Study Participation includes:
• Screening period (up to 2 weeks) – check whether you can participate in the study
• Run-In period (4 weeks) – prior to randomization, participants will be educated on the study expectations including use of hand-help spirometer (a device used to measure the amount of are you breathe in and breathe out) and electronic diary (e-diary)
• Treatment period (12 weeks) – eligible participants will be randomly assigned (like pulling a number out of a hat) to receive the investigational drug, comparator (an asthma drug already on the market), or placebo. A Placebo looks like the investigational drug but contains no active ingredients
• Follow-Up (1 week) – at the end of the treatment period, you will have some final study assessments, including to check for any adverse reactions you may have experienced.